Founded in 2010, TESARO aims to identify, acquire, and develop promising drug candidates to commercialize safer and more effective cancer therapies. They are currently developing rolapitant, a neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting. TESARO is also advancing its ALK inhibitor program for oncology indications. With a team of experienced executives, the company plans to commence Phase 3 clinical testing of rolapitant in 2011 and initiate the first ALK inhibitor clinical trial in 2012. TESARO was co-founded by former executives of MGI PHARMA, which was acquired by Eisai Co., Ltd. for $3.9 billion. Headquartered in Waltham, Massachusetts, TESARO focuses on developing and commercializing cancer therapeutics in North America, Europe, and China. As an oncology-focused business within GlaxoSmithKline (GSK), TESARO is committed to improving the oncology experience and providing unconditional care to people living with cancer.